Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

NCT03775850 is registered in ClinicalTrials.gov with Evelo Biosciences, Inc. as lead sponsor.

NCT NCT03775850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03775850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Lead sponsor
Evelo Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 19, 2018
Completion date
October 31, 2021
Enrollment
69 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer metastatic, gastroesophageal cancer, msi-h, non small cell lung cancer, renal cell carcinoma, triple negative breast cancer